Baijin Life Science Holdings Limited
MNNGF
$0.08
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.73M | 9.79M | 6.86M | 7.39M | 7.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.73M | 9.79M | 6.86M | 7.39M | 7.92M |
| Cost of Revenue | 9.24M | 6.89M | 4.55M | 6.06M | 7.58M |
| Gross Profit | 3.49M | 2.90M | 2.31M | 1.33M | 341.70K |
| SG&A Expenses | 4.72M | 4.16M | 3.60M | 3.29M | 2.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -472.40K | -279.20K | -86.50K | -300.70K | -515.40K |
| Total Operating Expenses | 13.49M | 10.77M | 8.06M | 9.05M | 10.04M |
| Operating Income | -753.80K | -976.30K | -1.20M | -1.66M | -2.12M |
| Income Before Tax | -704.00K | -897.40K | -1.09M | -794.20K | -497.90K |
| Income Tax Expenses | 335.80K | 168.70K | 2.00K | 1.00K | -- |
| Earnings from Continuing Operations | -1.04 | -1.07 | -1.09 | -0.80 | -0.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -413.70K | -136.40K | 140.30K | 70.20K | -- |
| Net Income | -1.45M | -1.20M | -952.20K | -725.10K | -497.90K |
| EBIT | -753.80K | -976.30K | -1.20M | -1.66M | -2.12M |
| EBITDA | -460.10K | -786.80K | -1.11M | -1.60M | -2.10M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.66B | 2.62B | 2.58B | 2.57B | 2.56B |
| Average Diluted Shares Outstanding | 2.66B | 2.62B | 2.58B | 2.57B | 2.56B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |